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Introduction {#jcsm12101-sec-0001}
============

Fatigue is a common symptom in palliative care patients, and virtually, every intervention used to treat cancer, as well as the primary disease itself, may cause or contribute to fatigue. In a study of 1000 patients in an American palliative care programme, fatigue, weakness, and lack of energy were three of the five most frequently reported symptoms with a prevalence of 84%, 66%, and 61%, respectively.[1](#jcsm12101-bib-0001){ref-type="ref"} Fatigue is also commonly reported in non‐cancer patients with progressive life‐threatening diseases, such as multiple sclerosis and .amyotrophic lateral sclerosis,[2](#jcsm12101-bib-0002){ref-type="ref"} chronic obstructive pulmonary disease,[3](#jcsm12101-bib-0003){ref-type="ref"} heart failure,[4](#jcsm12101-bib-0004){ref-type="ref"} HIV,[5](#jcsm12101-bib-0005){ref-type="ref"} as well as chronic heart, kidney, or lung diseases.[6](#jcsm12101-bib-0006){ref-type="ref"}, [7](#jcsm12101-bib-0007){ref-type="ref"} Several drugs, such as the new anti‐neoplastic therapies, or drugs regularly used in palliative care have sedative properties, for example, opioid analgesics, benzodiazepines, antidepressants, or anticonvulsants can cause fatigue.[8](#jcsm12101-bib-0008){ref-type="ref"}

The pathophysiology of fatigue in palliative care patients is not fully understood. 'Primary fatigue' has been said to be related to the high cytokine load. Disease‐related symptoms, such as sleep disturbances, may also account for fatigue and may be termed 'secondary fatigue'. There are several definitions of fatigue. For this Cochrane review, we selected the definition of the European Association of Palliative Care: 'Fatigue is a subjective feeling of tiredness, weakness, or lack of energy'.[8](#jcsm12101-bib-0008){ref-type="ref"}

Assessment of fatigue will depend on subjective self‐assessment by the patient, substituted by caregiver or medical staff estimations only where self assessment is not possible. Single‐item scales have been proposed, and a multitude of checklists and questionnaires with multiple dimensions have been validated.[9](#jcsm12101-bib-0009){ref-type="ref"} It is possible that a number of hindrances such as lack of consensus on the definition of fatigue or on significant cut‐off levels of evaluation instruments limited structured approach with assessment and treatment steps have led to underestimation and undertreatment fatigue.

If possible, a causative treatment approach should be addressed. Most patients will require symptomatic treatment of fatigue with pharmacological and non‐pharmacological therapies. Some studies[10](#jcsm12101-bib-0010){ref-type="ref"}, [11](#jcsm12101-bib-0011){ref-type="ref"} have examined the role of non‐drug treatments for cancer‐related fatigue, such as patient education with provision of information on fatigue and its treatment, keeping a diary, energy expenditure planning, and physical exercise. On the other hand, there is a growing body of evidence that gives examples of effective pharmacological treatments for fatigue.[12](#jcsm12101-bib-0012){ref-type="ref"}, [13](#jcsm12101-bib-0013){ref-type="ref"}, [14](#jcsm12101-bib-0014){ref-type="ref"} Several recent systematic reviews[15](#jcsm12101-bib-0015){ref-type="ref"}, [16](#jcsm12101-bib-0016){ref-type="ref"}, [17](#jcsm12101-bib-0017){ref-type="ref"} have covered some drugs used to treat fatigue in cancer patients.

This paper provides an executive summary of a recent Cochrane Collaboration systematic review,[18](#jcsm12101-bib-0018){ref-type="ref"} which synthesizes evidence for the evaluation of the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases. The review updated the original review,[19](#jcsm12101-bib-0019){ref-type="ref"} 'Pharmacological treatments for fatigue associated with palliative care' and also incorporated the review 'Drug therapy for the management of cancer‐related fatigue'.[16](#jcsm12101-bib-0016){ref-type="ref"}

Materials and methods {#jcsm12101-sec-0002}
=====================

Eligibility criteria {#jcsm12101-sec-0003}
--------------------

Criteria for review entry were randomized controlled trials with focus on pharmacological treatment involving adults (≥18 years, both sexes), suffering fatigue in palliative care or in terminal illness. Participants could receive anti‐cancer treatment.

Outcome measures {#jcsm12101-sec-0004}
----------------

Patient‐reported fatigue and the improvement of fatigue were the primary outcomes of this review, while the secondary outcomes included asthenia, weakness, tiredness, exhaustion, and treatment‐related burden.

Search strategy {#jcsm12101-sec-0005}
---------------

We re‐engineered the search strategy (filter) of the previous review by Peuckmann‐Post *et al.* [19](#jcsm12101-bib-0019){ref-type="ref"} to facilitate the combination with another review by Minton *et al*.[16](#jcsm12101-bib-0016){ref-type="ref"} To identify studies for inclusion in this updated review, we developed a detailed search strategy for each electronic database and other resources. To validate the search strategy, we selected sentinel studies.[20](#jcsm12101-bib-0020){ref-type="ref"}, [21](#jcsm12101-bib-0021){ref-type="ref"} The following electronic databases were searched from their inception until 28 April 2014 CENTRAL, MEDLINE (Ovid), PsycINFO (Ovid), and EMBASE. Additional information was obtained from standard textbooks on palliative medicine, unpublished literature through searches of conference proceedings and also from experts in the field of palliative care.

Data collection and analysis {#jcsm12101-sec-0006}
----------------------------

Two review authors extracted the data (M. M. and M. C.) using a standard data extraction form and reviewed the data from the included studies. Two other authors (L. R. and H. C.) cross‐checked and sub‐sampled the data. We contacted the original investigators when dealing with the missing data. Two authors (M. M. and M. C.) independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion or by involving other review authors (L. R. and H. C.). Subgroup analysis was performed for dealing with following different criteria; type of drug, type of disease, and type of assessment tools.

Results {#jcsm12101-sec-0007}
=======

We identified 1645 publications in the search. After we removed 186 duplicate studies, we retrieved articles against the inclusion criteria and found 45 studies, which met the inclusion criteria (*Figure* [1](#jcsm12101-fig-0001){ref-type="fig"}). In total, we analysed data from 18 drugs, nine type of disease, and 4696 participants. Only two[21](#jcsm12101-bib-0021){ref-type="ref"}, [22](#jcsm12101-bib-0022){ref-type="ref"} of the treatment groups in this review were large enough to give a low risk of bias (200 participants or more per treatment arm). Most studies reported some benefit of the active treatment. In general, adverse reactions were mild and had little or no impact.

![Study flow diagram.[18](#jcsm12101-bib-0018){ref-type="ref"}](JCSM-7-023-g001){#jcsm12101-fig-0001}

We used studies investigating pemoline and modafinil in participants with multiple sclerosis‐associated fatigue and methylphenidate in participants suffering from cancer and fatigue for meta‐analysis. However, the US Food and Drug Administration (FDA) has decided to withdraw pemoline products (marketed as Cylert) because of the risk of liver toxicity, which outweighs the benefits of the drug.

Methylphenidate in cancer {#jcsm12101-sec-0008}
-------------------------

Meta‐analysis was performed for two studies,[23](#jcsm12101-bib-0023){ref-type="ref"}, [24](#jcsm12101-bib-0024){ref-type="ref"} which used the Functional Assessment for Chronic Illness Therapy ‐ Fatigue as the assessment tool in fatigue, comparing methylphenidate with placebo. The studies showed a slightly superior effect of methylphenidate compared with placebo (standardized mean difference 0.49, 95% confidence interval 0.15 to 0.83; *Figure* [2](#jcsm12101-fig-0002){ref-type="fig"}).

![Forest plot of comparison of methylphenidate vs. placebo in cancer: Functional Assessment for Chronic Illness Therapy ‐ Fatigue score change.[18](#jcsm12101-bib-0018){ref-type="ref"}](JCSM-7-023-g002){#jcsm12101-fig-0002}

Modafinil in multiple sclerosis {#jcsm12101-sec-0009}
-------------------------------

Modafinil was tested in 115 patients with multiple sclerosis,[25](#jcsm12101-bib-0025){ref-type="ref"} but failed to demonstrate the superiority of modafinil vs. placebo. Another recent study of 21 patients with multiple sclerosis showed positive effect of modafinil.[2](#jcsm12101-bib-0002){ref-type="ref"} However, this result must be interpreted with caution because of the small participant numbers. Meta‐analysis of these two studies also failed to demonstrate a significant effect, with a standardized mean difference of −0.14 (*Figure* [3](#jcsm12101-fig-0003){ref-type="fig"}).

![Forest plot of comparison of modafinil in cancer.[18](#jcsm12101-bib-0018){ref-type="ref"}](JCSM-7-023-g003){#jcsm12101-fig-0003}

Discussion {#jcsm12101-sec-0010}
==========

The aim of the Cochrane review[18](#jcsm12101-bib-0018){ref-type="ref"} was to evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases.

Our search strategy allowed us to identify all relevant studies. We identified 45 studies for inclusion, with a wide range of underlying diseases and drug interventions. Treatment results pointed to weak and inconclusive evidence for the efficacy of amantadine, pemoline, and modafinil in multiple sclerosis and for carnitine and donepezil in cancer‐related fatigue. Meta‐analysis shows an estimated superior effect for methylphenidate in cancer‐related fatigue, but not for modafinil in multiple sclerosis. Further studies about the efficacy and safety of potential medicines for fatigue treatment such as acetylsalicylic acid, mistletoe extract, megestrol acetate, and medroxyprogesterone acetate are needed.

Many of the included studies involved only a small number of participants and did not follow a consistent research methodology. In some cases, the investigated population was very heterogeneous, and any outcome may have been associated with depression, making it difficult to distinguish from primary fatigue. These limitations made it difficult to compare the methodological quality across the studies.

There are many possible causes of secondary fatigue. Unfortunately, little evidence from randomized trials is available on the efficacy of these treatments. In clinical practice, any potential cause for secondary fatigue should be treated.

The results of the literature search indicate that recent research interest focuses on modafinil, which seems a promising agent to diminish fatigue for palliative care patients. This may be an interesting perspective for the future.

Conclusions {#jcsm12101-sec-0011}
===========

There is insufficient evidence to support the use of a specific medicine to treat fatigue in palliative care patients. In this regards, amantadine showed the promised benefit in patients with multiple sclerosis with fatigue and methylphenidate in patients with cancer‐related fatigue. Further trials are needed for several medicines, which were used in some studies with positive results such as dexamethasone, methylprednisolone, acetylsalicylic acid, armodafinil, amantadine, and L‐carnitine. To enhance the interpretation and generalization of findings from relevant study populations, randomized controlled trials with larger participant number are required. Consensus is needed regarding fatigue definition and outcome parameters for clinical trials.
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